Sepsis-Related Outcomes of Patients with Philadelphia-Negative Myeloproliferative Neoplasms

Cancer Invest. 2023 May;41(5):423-431. doi: 10.1080/07357907.2023.2187059. Epub 2023 Mar 8.

Abstract

We analyzed the National Inpatient Sample (NIS) database to study the sepsis-related outcomes in patients with Philadelphia negative myeloproliferative neoplasms (MPN). A total of 82,087 patients were included, most had essential thrombocytosis (83.7%), followed by polycythemia vera (13.7%), and primary myelofibrosis (2.6%). Sepsis was diagnosed in 15,789 (19.2%) patients and their mortality rate was higher than nonseptic patients (7.5% vs 1.8%; p < .001). Sepsis was the most significant risk factor of mortality (aOR, 3.84; 95% CI, 3.51-4.21), others included liver disease (aOR, 2.42; 95% CI, 2.11-2.78), pulmonary embolism (aOR, 2.26; 95% CI, 1.83-2.80), cerebrovascular disease (aOR, 2.05; 95% CI, 1.81-2.33), and myocardial infarction (aOR, 1.73; 95% CI, 1.52-1.96).

Keywords: Sepsis; mortality; polycythemia vera; primary myelofibrosis; thrombocytosis.

MeSH terms

  • Humans
  • Myeloproliferative Disorders* / complications
  • Myeloproliferative Disorders* / diagnosis
  • Myeloproliferative Disorders* / epidemiology
  • Polycythemia Vera* / complications
  • Polycythemia Vera* / diagnosis
  • Primary Myelofibrosis* / diagnosis
  • Sepsis* / epidemiology
  • Thrombocythemia, Essential* / diagnosis